IMMUNOBIOLOGY

The TLR-mediated response of plasmacytoid dendritic cells is positively regulated by estradiol in vivo through cell-intrinsic estrogen receptor α signaling

Cyril Seillet,[1-3] Sophie Laffont,[1-3] Florence Trémollières,[4-6] Nelly Rouquié,[1-3] Claude Ribot,[4-6] Jean-François Arnal,[4,5] Victorine Douin-Echinard,[4,5] Pierre Gourdy,[4,5] and Jean-Charles Guéry[1-3,5]

[1]Inserm, U1043, Toulouse, France; [2]Centre National de la Recherche Scientifique, U5282, Toulouse, France; [3]Université de Toulouse, Université Paul Sabatier, Centre de Physiopathologie de Toulouse Purpan, Toulouse, France; [4]Inserm, U1048, Institut des Maladies Métaboliques et Cardiovasculaires, Toulouse, France; [5]Centre Hospitalier Universitaire, Toulouse, France; and [6]Centre de Ménopause, Hôpital Paule de Viguier, Toulouse, France

Plasmacytoid dendritic cells (pDCs) produce large amounts of type I interferons (IFN-α/β) in response to viral or endogenous nucleic acids through activation of their endosomal Toll-like receptors (TLR-7 and TLR-9). Enhanced TLR-7–mediated IFN-α production by pDCs in women, compared with men, has been reported, but whether sex hormones, such as estrogens, are involved in this sex-based difference is unknown. Here we show, in humanized mice, that the TLR-7–mediated response of human pDCs is increased in female host mice relative to male. In a clinical trial, we establish that treatment of postmenopausal women with 17β-estradiol markedly enhances TLR-7– and TLR-9–dependent production of IFN-α by pDCs stimulated by synthetic ligands or by nucleic acid-containing immune complexes. In mice, we found exogenous and endogenous estrogens to promote the TLR-mediated cytokine secretion by pDCs through hematopoietic expression of estrogen receptor (ER) α. Genetic ablation of ERα gene in the DC lineage abrogated the enhancing effect of 17β-estradiol on their TLR-mediated production of IFN-α, showing that estrogens directly target pDCs in vivo. Our results uncover a previously unappreciated role for estrogens in regulating the innate functions of pDCs, which may account for sex-based differences in autoimmune and infectious diseases. (*Blood*. 2012;119(2):454-464)

Introduction

Dendritic cells (DCs) are specialized sentinels in the immune system that detect invading pathogens and play a crucial role in orchestrating the immune responses. In response to viral infection, a specialized DC subset, plasmacytoid DCs (pDCs), produces a large amount of type I IFNs (IFN-α/β), which are potent anti–viral and immunostimulatory cytokines.[1] pDCs become activated to produce IFN-α/β through Toll-like receptors (TLR-7 and TLR-9) within endosomal compartments that can sense viral nucleic acids. In the context of autoimmune diseases, such as systemic lupus erythematosus (SLE), these TLRs can also be inappropriately activated by self-nucleic acids complexed with autoreactive antibodies, resulting in IFN-α production by pDCs.[2] Activation of pDCs by endogenous DNA and RNA has been suggested to play a critical role in promoting and exacerbating SLE.[2-4] SLE patients show increased serum levels of IFN-α and overexpression of IFN-α-regulated genes in blood cells, suggesting a central role for type I IFNs in disease pathogenesis.[5-8] This is supported by the observation that antinuclear antibody and SLE syndrome can develop during IFN-α treatment in patients with nonautoimmune disorders.[9] Likewise, IFN-α administration accelerates disease development and enhances disease severity in lupus-prone mouse strains.[10,11] In addition to IFN-α, TNF-α has been shown to be increased in the serum of patients with active SLE disease and correlates with IFN-α levels.[12,13] Although pDCs can also produce TNF-α, it is not clear whether they represent the unique source of this cytokine in SLE.[14]

Cumulative evidence supports a role for sex-based differences in the pathogenesis of autoimmune and infectious diseases, which may be the result of sex hormones through their effects on innate and adaptive immunity.[15,16] A strong sex bias is observed in SLE, whose incidence is approximately 9 times higher in women relative to men.[15] Because disease onset is much more frequent in women of childbearing age, it has been hypothesized that sex steroid hormones, such as estrogens, could be responsible for the sex bias in lupus susceptibility.[15,17] In support of this, it has been shown in murine models of SLE that administration of 17β-estradiol (E_2) accelerated disease onset and increased its severity.[18,19] Interestingly, marked sex differences have been also reported in susceptibility to HIV-1 pathogenesis, with women having a higher risk of developing AIDS compared with men infected with a similar viral load.[20,21] Given the central role of pDCs in these diseases, it is probable that common sex-linked factors influencing pDC innate functions could contribute to this major sexual dimorphism. In agreement with this hypothesis, a marked increase in the TLR-7–mediated IFN-α production by women pDCs, compared with men, has been recently reported in healthy subjects.[22,23] Interestingly, in the study by Meier et al,[23] there was a trend toward a lower frequency of IFN-α–producing pDCs in postmenopausal women compared with premenopausal ones, suggesting that female sex hormones could regulate the TLR-mediated responses of pDCs. However, direct evidence for a role of female steroid hormones in the regulation of pDC innate functions is still lacking.

In this study, we investigated whether estradiol could regulate the innate functions of human and mouse pDCs in vivo. Altogether, our results highlight a new property of estrogens in promoting the

---

TLR-mediated innate functions of pDCs in both humans and mice in vivo, through pDC-intrinsic estrogen receptor (ER) α signaling.

Methods

Subjects and study design

Postmenopausal volunteers (46-59 years old) were included in the study after they had given their written informed consent in accordance with the Declaration of Helsinki. The study was reviewed and approved by a national institutional review committee and the regional ethical committee (Affsaaps 060149–00; CPPRB 2–06-09). Three blood samples were collected. The 2 first samples were collected within a 2- to 3-week interval before estrogen treatment. The women were then randomized into 2 groups to receive either transdermal E_2 (Estrapatch, 60 µg/24 hours; n = 15) or oral E_2 (Estrofem, 2 mg/day; n = 13) for 30 days. The last blood sample was collected at the end of the E_2 treatment period. For the comparison between men and women, fresh blood samples from healthy donors (18-45 years) were obtained from Etablissement Français du Sang.

Mice

NOD/SCID/$\beta 2m^{-/-}$ mice, obtained from Plateforme de Haute Technologie (Université Joseph Fourier), were sublethally irradiated (120 cGy) at the age of 4 weeks and were injected intravenously with 1 to 2×10^5 $CD34^+$ hematopoietic progenitor cells purified from umbilical cord blood as described.[24] Eight weeks after reconstitution, human bone marrow cells were negatively enriched by magnetic depletion of mouse cells using anti–mouse CD45.1-biotin mAb (A20) and anti–biotin microbeads (Miltenyi Biotec). The frequency of human pDCs producing IFN-α and TNF-α in response to the TLR-7/TLR-8 ligand R-848 was then determined as detailed in "Intracellular cytokine staining of pDCs."

Female C57BL/6 (B6) mice were purchased from the Center d'Elevage R. Janvier. ERα-deficient (ERα$^{-/-}$) B6 mice (CD45.2), which have a deletion in exon 2 of the ERα gene (*Esr1*), have been previously described[25] and backcrossed into the B6 background for at least 10 generations. Mice selectively lacking ERα in the hematopoietic compartment or in the DC lineage were generated by crossing B6 mice carrying an *Esr1* gene in which exon 2 was flanked by loxP sites (ERα$^{fl/fl}$) with B6 mice expressing the Cre recombinase under the control of the Tie2 promoter-enhancer (Tie2-ERα^{KO}) or the CD11c promoter (CD11c-ERα^{KO}), respectively, as described elsewhere.[26] Mice were maintained in our animal facilities under pathogen-free conditions. Unless otherwise stated, 8- to 12-week-old mice were used in all experiments. All protocols used in mice experiments were approved by the Inserm U1043 Institutional Review Board for animal experimentation.

Where indicated, animals were castrated or sham-operated at 4 weeks. Eight-week-old mice that received exogenous E_2 were treated for 2 to 3 weeks by subcutaneous implantation of low-dose E_2 pellets (0.05 mg, 60-day release, Innovative Research of America). These E_2 pellets have been shown to result in the maintenance of a constant serum E_2 concentration of 34 pg/mL, corresponding to estrus levels.[27]

IFN-α production by human PBMCs and mouse pDCs.

Human PBMCs (5×10^5 cells/well) isolated from whole blood were suspended in X-Vivo 15 medium (Cambrex) and stimulated with titrated amounts of TLR-9 ligand CpG-2216 (Invivogen). For some subjects, PBMCs were stimulated with SLE serum in the presence of necrotic supernatant from PBMCs as described.[28] Human IFN-α was measured by ELISA (PBL InterferonSource) in 24-hour culture supernatants. Data from the ELISA tests were normalized on the basis of the respective percentage of pDCs present in the PBMC fraction to show IFN-α production on a per-pDC basis. These results were used to compute at each time point an IFN-α score by summing the data obtained for the different doses of CpG-2216 tested (supplemental Methods, available on the *Blood* Web site; see the Supplemental Materials link at the top of the online article).

Mouse pDCs ($B220^+$, mPDCA-1^+) were sorted using a FACSAria (BD Biosciences) and were stimulated in 96-well plates (40-75 $\times 10^3$ cells/well)

for 24 hours with CpG-2216. All stimulations were made in RPMI 1640 (Eurobio) complete medium supplemented with 10% heat-inactivated FCS (ATGC Biotechnologie). To measure the pDC-mediated IFN-α response in vivo,[29] mice were injected intravenously with 2 µg CpG-2216 mixed with 1,2-dioleoyloxy-3-trimethylammonium-propane (Roche Diagnostics). Serum IFN-α production was assessed by ELISA (PBL InterferonSource).

Intracellular cytokine staining of pDCs.

Human PBMCs and mouse cell-depleted bone marrow cells from humanized mice were stimulated with 1 to 3 µg/mL R-848 (Invivogen) during 5 hours. Brefeldin A (eBioscience) was added for the last 3 hours of culture. Human PBMCs were surface labeled with anti–BDCA2-APC (Miltenyi Biotec) and anti–Lin-FITC antibodies and BM cells from humanized mice with anti–human CD45-PE–Cy7, anti–CD123-PE–Cy5, and anti–BDCA4-APC. Cells were then fixed, permeabilized, and stained for intracellular cytokine production using anti–IFN-α–PE (Miltenyi Biotec) or anti–TNF-α–Alexa700 (BD Biosciences) antibodies.

Mouse bone marrow cells suspensions were activated with 2 µg/mL R848 (Invivogen), or preparation of oligonucleotides PolyU (Sigma-Aldrich) or CpG-2216 (Invivogen) mixed with 1,2-dioleoyloxy-3-trimethylammonium-propane for 3 to 4 hours. Brefeldin A (eBioscience) was added for the last 2 hours of culture. Bone marrow cell suspensions were then stained with PECy7-labeled antibodies specific for mouse CD11c (N418) or B220 (RA3–6B2), and mPDCA1-APC (all from eBioscience). Cells were then fixed and stained intracellularly with mixed FITC-labeled IFN-α/β-specific antibodies (RMMA-1/RMMB-1; PBL), PE-labeled TNF-α (MP6-XT2; BD Biosciences), and anti–IL-12p40–PerCP-Cy5 (C15.6; BD Biosciences). Data were acquired on a LSR II (BD Biosciences).

Statistical analysis

Data were analyzed using GraphPad Prism Version 4.03 (GraphPad Software). The effect of E_2 treatment on cytokine production by TLR-stimulated pDCs from postmenopausal women was assessed by the 2-tailed Wilcoxon signed rank test. Differences between groups were otherwise analyzed by the 2-tailed Mann-Whitney *U* test.

Results

Sex-based differences determine the TLR-7–mediated response of human pDCs in vivo

It has been recently reported that pDCs from women compared with men exhibited an enhanced capacity to produce type I IFNs when stimulated with TLR-7/TLR-8 ligands.[22,23] We first confirmed these results by measuring the frequency of IFN-α– and TNF-α–producing pDCs in response to short term ex vivo stimulation of PBMCs from healthy female and male donors with the TLR-7/TLR-8 ligand R-848. In agreement with previous works,[23] we observed an increased frequency of pDCs producing not only IFN-α but also TNF-α in response to TLR-7 stimulation in women of child-bearing potential compared with age-matched men (Figure 1A-B).

However, it is not clear whether this bias is the result of gene dosage effect because TLR-7 is encoded on the X chromosome, differences in other X chromosome-linked genetic factors, or differences in the production of sex steroid hormones. To address this issue, we evaluated the TLR-mediated response of human pDCs from different female donors that developed in a male or female environment using a well-established model of humanized mice.[24] Sublethally irradiated NOD/SCID/$\beta 2m^{-/-}$ mice of either sex were transplanted with $CD34^+$ hematopoietic progenitor cells from healthy female donors. Eight weeks after transplantation, bone marrow cells from these humanized mice were depleted of hematopoietic cells of mouse origin and stimulated in vitro with a

Figure 1. Sex-based differences control the TLR-7-mediated response of human pDCs in vivo. (A-B) pDCs derived from premenopausal women (18-45 years old, n = 20) or age-matched male donors (n = 15) were stimulated with TLR-7/TLR-8 ligand R-848 and stained for IFN-α and TNF-α. Percentage of IFN-α (A) and TNF-α (B) positive pDCs in premenopausal women (18-45 years old, n = 20) compared with men (n = 15). (C-E) Female or male NOD/SCID/β2m$^{-/-}$ were sublethally irradiated and transplanted with human CD34$^+$ hematopoietic progenitor cells from 3 different female donors. (C) After 8 weeks, human pDCs were identified as the CD45$^+$ CD123$^+$ BDCA-4$^+$ compartment in bone marrow cells. (D-E) Bone marrow cells were restimulated ex vivo as in panel A. The frequencies of IFN-α (D) and TNF-α (E) producing pDCs were determined by flow cytometry. Horizontal lines in scatter plots on the right panels indicate mean values. Statistical difference between groups was assessed using the Mann-Whitney U test.

TLR-7/TLR-8 ligand to assess the frequency of IFN-α– or TNF-α–producing pDCs as described in Figure 1A-B. The frequency of CD123$^+$ BDCA-4$^+$ pDCs among human CD45$^+$ cells in the bone marrow was not affected by the sex of the recipient mice (Figure 1C). In striking contrast, the frequency of IFN-α^+ pDCs was significantly increased in female compared with male mice (Figure 1D). Interestingly, the mean frequencies of IFN-α^+ pDCs measured in humanized male and female mice were similar to those obtained in sex-matched human donors, with female pDCs exhibiting a 1.8-fold increase frequency of IFN-α–producing cells compared with male ones (Figure 1A,D). Similar results were obtained by analyzing the production of TNF-α (Figure 1E). Again, pDCs that developed in a female environment exhibited an increased frequency of TNF-α–producing cells compared with male ones (Figure 1E). A similar tendency was observed when we analyzed the murine pDC response after R-848 stimulation in the same

humanized NOD/SCID/β2m$^{-/-}$ mice (not shown). However, this sex-dependent difference was not found in C57BL/6 mice (data not shown). Altogether, these data show that the TLR-7–mediated response of human pDCs is shaped by the sex of the host rather than cell-intrinsic X-linked genetic factors.

Exogenous and endogenous estrogens selectively enhance the R-848–mediated responses of human pDCs but not monocytes

To investigate whether estrogens were responsible for this sexual dimorphism, we evaluated the effect of E$_2$ treatment on the TLR-mediated response of pDCs in early postmenopausal women in a longitudinal clinical trial. In this study, blood samples were obtained at 3 time points over a period of up to 2 months. To evaluate the intraindividual variability of the different parameters analyzed, 2 PBMC samples (S1 and S2) were collected before treatment, 2 to 3 weeks apart. Estrogen therapy was initiated just after the S2 collection, and the last blood sample (S3) was taken one month later (Figure 2A). The absolute numbers and relative abundances of conventional DCs (cDCs) and pDCs were constant in samples S1 and S2 from each person before treatment and were not modified after one month of E$_2$ administration (supplemental Figure 1A-B). In addition, the percentages of distinct DC subsets among purified PBMCs were stable (supplemental Figure 1C). Thus, administration of E$_2$ in postmenopausal women did not affect blood DC subset counts, including pDCs.

At each time point, we stimulated PBMCs with the TLR-7/TLR-8 ligand R-848 and analyzed IFN-α and TNF-α production in Lin$^-$ BDCA-2$^+$ pDCs (supplemental Figure 2A). Before E$_2$ treatment, the average frequencies of IFN-α- and TNF-α–producing cells among pDCs were 7.7% $\pm$ 5% and 2.1% $\pm$ 1.5%, respectively (mean $\pm$ SEM, Figure 2; supplemental Figure 2). There was no difference in the percentage of cytokine-producing pDCs at the 2 time points tested before E$_2$ therapy (supplemental Figure 2). Of note, the percentages of IFN-α– or TNF-α–producing pDCs in TLR-7–stimulated PBMCs were significantly higher ($P < .001$) in premenopausal women (Figure 1A-B) compared with postmenopausal women (Figure 2C,E). These differences were probably the result of estrogen deprivation because the proportions of TLR-7–stimulated pDC-producing IFN-α (Figure 2B-C) or TNF-α (Figure 2D-E) were significantly increased after one month of E$_2$ treatment, with a mean fold increase of 2.8 and 5.2, respectively. This enhancing effect of estrogens on the TLR-7–mediated response of pDCs did not require the presence of the hormone in vitro because addition of physiologic concentrations of E$_2$ to PBMC cultures did not modify the frequency of pDCs producing either IFN-α or TNF-α on stimulation via TLR-7 (supplemental Figure 3). Because this result was obtained with PBMCs from both untreated and E$_2$-treated postmenopausal women (supplemental Figure 3), we can conclude that the enhancing effect of estrogens on cytokine production by TLR-stimulated pDCs was established in vivo.

Because the TLR-7/TLR-8 ligand R-848 is also capable of triggering TNF-α production in monocytes through TLR-8,[30] we also analyzed the impact of menopause and E$_2$ supplementation on endosomal TLR responsiveness in this cell population (supplemental Figure 4). We focused our analysis on the FSC^{hi} SSC^{hi} flow cytometric fraction that is mainly composed of large monocytes expressing CD11c and CD14 (supplemental Figure 4A). In premenopausal women, the proportion of TNF-α–producing monocytes was similar to that of TNF-α-producing pDCs (mean $\pm$ SEM, 34.8% $\pm$ 13.4% vs 27.1% $\pm$ 12.7%, respectively). Interestingly,

Figure 2. E$_2$ administration increases the frequency of pDC producing IFN-α and TNF-α after TLR-7 stimulation. (A) The first 2 blood samples (S1 and S2) from early postmenopausal women volunteers were collected before E$_2$ treatment by oral or transdermal route with standard substitutive posology. The last blood sample (S3) was collected after 30 ± 3 days of treatment. (B,D) Representative flow cytometry plots showing IFN-α (B) and TNF-α (D) production by BDCA-2$^+$ pDCs derived from postmenopausal women before (left) or after E$_2$ treatment (right), after 5 hours of in vitro stimulation with TLR-7/TLR-8 ligand R-848. (C,E) Percentage of pDCs from postmenopausal women before (S2) and after E$_2$ treatment (S3), producing IFN-α (C, n = 17) or TNF-α (E, n = 21) on in vitro culture in the presence of R848. Horizontal bars indicate mean values, and P values were determined using the Wilcoxon signed rank test. (C,E) Dot plot panels show the correspondence between the values for each patient between mean S1-S2 versus S3.

whereas the frequency of TNF-α$^+$ pDCs dropped in postmenopausal women (from 27.1% ± 12.7% to 3.73% ± 4.7%), the percentage of TNF-α–producing monocytes in response to R-848 stimulation remained at a comparable level between premenopausal and postmenopausal women and was not affected by E$_2$ therapy in postmenopausal women (supplemental Figure 4C). Altogether, these data demonstrate that estrogens selectively up-regulate endosomal TLR-responsiveness in pDCs but not in monocytes.

E$_2$ treatment enhances TLR-9–mediated IFN-α production by pDCs in postmenopausal women

We next investigated whether the enhancing effect of E$_2$ on IFN-α production by pDCs was specific of TLR-7–mediated activation or could also be observed in response to TLR-9 stimulation of PBMCs using CpG-2216 oligonucleotides. CpG-2216 is primarily acting on pDCs and has been shown to trigger the production of IFN-α in whole PBMCs but not in PBMCs depleted of pDCs.[31] Before E$_2$ treatment, CpG-2216 triggered the production of IFN-α in a dose-dependent manner, with no significant differences between the S1 and S2 samples (Figure 3A-B). Interestingly, after one month of E$_2$ treatment, a strong increase in IFN-α production by CpG-stimulated PBMCs was observed in the majority of women (Figure 3C). The analysis of the TLR-9–responsiveness in 23 subjects demonstrated a highly significant enhancing effect of E$_2$ therapy (Figure 3C). When all data were normalized to S1 values,

there was a significant 3-fold increase on average in IFN-α scores after E$_2$-treatment (Figure 3D).

E$_2$ enhances IFN-α production by pDCs stimulated with self-nucleic acid-containing immune complexes

Autoantibodies found in the serum of SLE patients in the form of immune complexes containing self-DNA or RNA are potent inducers of type I IFN production by pDCs through activation of TLR-9 or -7, respectively.[32,33] We also analyzed the effect of E$_2$ treatment on the production of IFN-α by PBMCs from postmenopausal women stimulated with SLE sera. In agreement with previous work by others,[28] SLE sera could induce IFN-α secretion by PBMCs only in the presence of necrotic supernatants (Figure 4A). In postmenopausal women, the production of IFN-α in response to SLE serum was usually low and, when normalized to the number of pDC, represented in average (± SD) 0.068 ± 0.06 pg/mL/pDC (Figure 4B). Interestingly, after E$_2$-treatment we observed a marked up-regulation of IFN-α production by PBMCs cocultured with SLE sera (Figure 4A). After normalization to pDC numbers, we found a significant stimulatory effect of E$_2$ administration on the IFN-α response of PBMCs stimulated by SLE sera in the 6 subjects tested in this assay (Figure 4B). The increase in IFN-α production (to 0.21 ± 0.06 pg/mL/pDC) corresponded to a 1.7- to 15-fold change relative to the response obtained before E$_2$ treatment (Figure 4B). These data show that in vivo exposure to E$_2$

Figure 3. E₂ treatment enhances IFN-α production by TLR-9 ligand-stimulated pDCs in postmenopausal women. (A) PBMCs purified from whole blood were cultured at 5×10^5 cells/well in the presence of indicated concentrations of CpG-2216. IFN-α concentration was measured by ELISA in 24-hour culture supernatants. The IFN-α range measured for 1 μg/mL of CpG was from 21 pg/mL to 2914 pg/mL. Data were normalized to the number of pDCs present in PBMCs, as determined by flow cytometry. Data from 8 representative subjects are shown, before (dashed lines) or after E₂ treatment (solid line). Numbers in parentheses show the fold increase of IFN-α production as calculated in panel D. (B-C) Normalized IFN-α production before (B) and after (C) E₂ treatment was calculated by summing the concentrations of IFN-α measured in response to the different concentrations of CpG as shown in panel A (n = 23). Dot plot panels show the correspondence between the values for each patient in samples S1 versus S2 (B) and S2 versus S3 (C). (D) Data from samples S2 and S3 were expressed as fold increase of normalized IFN-α production relative to the S1 and mean S1-S2 values, respectively. Individual data are shown, and horizontal bars indicate mean values. P values were determined using the Wilcoxon signed rank test.

conditions blood pDCs to enhanced TLR-dependent production of IFN-α in response to nucleic acid containing immune complexes.

Endogenous and exogenous estrogens enhance cytokine production by mouse pDCs after TLR-7/TLR-9 stimulation

We next sought to understand the mechanisms involved in the E₂-amplifying effect on the TLR-dependent response of pDCs in mice. We first analyzed whether endogenous estrogens could influence pDC response to TLR stimulation by comparing female mice that were ovariectomized (Ovx) or not before their sexual maturity. We found that ovariectomy was associated with

a 3-fold decrease in the frequency of bone marrow pDCs producing type I IFNs (Figure 5A) and with a significant decrease in pDCs producing TNF-α (Figure 5B) in response to TLR-7 triggering. These results suggested that endogenous estrogens enhanced the TLR-mediated response in mouse pDCs as well. To directly demonstrate this point, Ovx mice were supplemented or not with E₂ before the TLR-dependent responses of pDCs were examined. Although E₂ supplementation decreased the overall bone marrow cellularity (not shown), the absolute number of pDCs was not significantly different between E₂-treated and control Ovx mice (Figure 5C). In response

Figure 4. E₂ treatment enhances IFN-α production induced by nucleic acid-containing immune complexes present in sera from SLE patients. PBMCs from postmenopausal women (5×10^5 cells/well) were stimulated with 1% SLE serum in the presence of different concentrations of necrotic supernatant from frozen-thawed (FT) PBMCs. IFN-α concentration in 24-hour culture supernatants was measured by ELISA. (A) IFN-α production by PBMCs from 2 representative postmenopausal women before (open bar) or after transdermal E₂-therapy (solid bar). (B) Data obtained from 6 subjects before (S2) and after (S3) E₂ treatment. PBMCs were stimulated as in panel A with 1% SLE serum with 15% FT, and IFN-α production was normalized to pDC numbers and expressed as picograms per milliliter pDCs. Individual data are shown, and bars represent mean values. P values were determined using the Wilcoxon signed rank test.

Figure 5. Endogenous and exogenous estrogens enhance pDC cytokine production after TLR-7/TLR-9 stimulation. Female WT C57BL/6 (B6) mice were ovariectomized (OVX) or not (Sham) before sexual maturity (3-4 weeks). In adulthood (7-8 weeks), bone marrow cells were restimulated ex vivo in the presence of R-848 for 3 hours. Dot plot showing the frequency of pDCs (mPDCA1$^+$) producing IFN-α/β (A) and TNF-α (B). The lines on scatter plots indicate mean values. Results from individual mice are shown. *P* values were determined using the Mann-Whitney *U* test. (C-E) Ovariectomized mice were treaded or not with E$_2$ (0.05-mg E$_2$ pellet, 60-day release) for 2 weeks. pDCs were stimulated with R-848 and analyzed for IFN-α (C) and TNF-α (D). (E) Purified bone marrow pDCs were stimulated with the TLR-9 ligand CpG-2216. Culture supernatant was collected after 24 hours of stimulation, and IFN-α (F) and TNF-α (G) were measured by ELISA. Data are representative of 2 or 3 independent experiments.


to TLR-7 stimulation, we found an enhanced frequency of pDCs producing not only IFN-α (Figure 5D) but also TNF-α (Figure 5E) in E$_2$-supplemented Ovx mice.

To make sure that these functional differences were the result of changes in the cell-intrinsic properties of pDCs, the specific population was isolated out of bone marrow cells before testing them for TLR activation in vitro using the TLR-9 ligand CpG-2216. We found a marked increase in the production of IFN-α (Figure 5F) and TNF-α (Figure 5G) by TLR-9–stimulated pDCs from E$_2$-treated mice. No cytokines were produced in the absence of TLR ligand (not shown). Together, these data showed that both endogenous and exogenous estrogens increase endosomal TLR-7 and TLR-9 responsiveness of mouse pDCs in vivo.

ERα-deficiency in bone marrow cells decreases pro-inflammatory cytokine production of pDCs after TLR-7/TLR-9 stimulation

To gain insight into the mechanisms involved, we determined whether the effect of estrogens on pDC innate functions was mediated through ERα signaling within the hematopoietic compartment. Because ERβ is not expressed in DC progenitors,[34] we decided to focus our analysis on ERα. To this end, female CD45.1 mice were sublethally irradiated and then reconstituted with either CD45.2 wild-type (WT) or ERα$^{-/-}$ bone marrow cells. After 3 weeks of reconstitution, we analyzed the pDC response after TLR-7– or TLR-9–triggering in the bone marrow of these chimeras. We found that ERα deficiency did not modify the percentage of pDCs derived

Figure 6. The enhancing effect of E_2 on the TLR-mediated responses of pDC is mediated through hematopoietic ERα. WT or ERα[−/−] B6 bone marrow cells were injected into lethally irradiated CD45.1 WT female B6 mice. After 3 weeks of reconstitution, bone marrow cells were stimulated with polyU (C), R848 (D), or GpG-2216 (E). (A) Dot plots showing the frequency of WT or ERα[−/−] pDCs (mPDCA1[+]CD45.1[−]). (B) Percentage of pDCs from individual mice. (C-E) Intracellular IFN-α/β staining of pDCs derived from ERα[+/+] or ERα[−/−] bone marrow cells. Stimulated pDCs were stained for IFN-α/β and analyzed by flow cytometry. Results from individual mice are shown. The lines on scatter plots indicate mean values. P values were determined using the Mann-Whitney U test. Data are representative of 3 independent experiments.

from the grafted cells (Figure 6A-B). When bone marrow cells were stimulated with TLR-7 ligands, poly(U) (Figure 6C), R-848 (Figure 6D), or TLR-9 ligand CpG (Figure 6E), the frequencies of IFN-α/β–producing pDCs were significantly reduced in bone marrow cells derived from ERα[−/−] compared with WT donors. This impaired pDC responsiveness in the absence of ERα was not limited to type I IFN but was also observed when we analyzed the frequency of pDCs producing TNF-α or IL-12p40 (supplemental Figure 5). Altogether, our results show that hematopoietic expression of ERα is required to mediate the in vivo enhancing effect of endogenous estrogens on the TLR-mediated responses of mouse pDCs in the bone marrow.

### E_2-mediated up-regulation of IFN-α production by TLR-9–activated pDCs is lost in mice lacking ERα in pDCs

E_2-mediated activation of ERα may act at distinct stages of pDC development to modulate their functional properties, either through cell-intrinsic or cell-extrinsic mechanisms within the hematopoietic compartment. To dissect at which stage of pDC development ERα activation is determinant, we compared the effect of E_2 treatment on the innate functions of pDCs isolated from mice lacking ERα within the whole hematopoietic compartment (Tie2-ERα[KO]) or more specifically in the DC lineage (CD11c-ERα[KO]). In the CD11c-ERα[KO] mice, Cre-mediated recombination removing the floxed genes has been shown to occur mainly in the DC lineage, with minimal deletion in lymphocytes and myeloid cells.[35] Although there was a tendency toward a slight reduction in immature pDC number in the bone marrow of E_2-treated mice, this effect was not significant and was not dependent on ERα expression (supplemental Figure 6A; Figure 7A). Absolute numbers of bone marrow pDCs were not altered by Cre-mediated ERα gene deletion whether mice were supplemented or not with E_2 (supplemental Figure 6A; Figure 7A). Thus, in agreement with data in Figure 6B, ERα signaling did not modify the absolute numbers of immature pDCs in the bone marrow. Next, pDCs were FACS-sorted (purity > 99%;

supplemental Figure 7) from the bone marrow of Ovx mice treated or not with E_2 and stimulated in vitro with CpG-2216. Whereas production of IFN-α (Figure 7B), TNF-α (Figure 7C), and IL-12p40 (Figure 7D) was similar between estrogen-deprived Ovx ERα[flox/flox] control and Ovx CD11c-ERα[KO] mice, enhanced cytokine production was observed in ERα[flox/flox] mice compared with CD11c-ERα[KO] mice in the presence of exogenous E_2. Similar results were obtained by comparing the TLR-9–mediated responses of bone marrow pDCs from control and Tie2-ERα[KO] mice (supplemental Figure 6). Again, a marked difference in the TLR-9–dependent production of IFN-α and TNF-α was seen between control ERα[flox/flox] and Tie2-ERα[KO] pDCs from E_2-treated mice (supplemental Figure 6B-C). By contrast, when pDCs were obtained from untreated Ovx mice, the cytokine responses were similar between both groups. Analysis of phenotypic markers on CpG-2216–stimulated pDCs did not show overt changes regarding the expression of mPDCA-1 and CD40 between pDCs from control or conditional knock-out mice, whether mice were supplemented or not with E_2 (supplemental Figure 7; and data not shown).

Lastly, we analyzed the impact of DC-specific ERα deficiency in intact female mice on the TLR-9–mediated response of bone marrow and splenic pDCs. A reduced production of IFN-α (Figure 7E) and TNF-α (Figure 7F) was observed in CpG-stimulated cultures of purified bone marrow pDCs from CD11c-ERα[KO] mice compared with their ERα[flox/flox] littermate controls. We then measured the kinetics of serum IFN-α production after intravenous injection of CpG-2216, which is primarily mediated by splenic pDCs.[29] Data in Figure 7G show that the production of IFN-α in CD11c-ERα[KO] was significantly lower at 3 hours compared with ERα[flox/flox] mice. Similar results were obtained in intact Tie2-ERα[KO] female mice injected intravenously with CpG, which exhibited a 2-fold reduction in the serum IFN-α concentration compared with ERα[flox/flox] control mice (supplemental Figure 6D).

Altogether, these results demonstrate that ERα signaling in pDCs in vivo regulates their capacity to produce type I IFNs on

Figure 7. ERα signaling in pDCs is required to mediate the enhancing effect of E₂ on the TLR-mediated production of IFN-α. (A-D) Ovariectomized CD11c-ERαKO female or ERαfl/fl control littermates on a B6 background were treated or not with E₂ as in Figure 5. (A) Absolute numbers of bone marrow pDCs from individual mice. *P* value was determined using the Mann-Whitney *U* test. pDCs were FACS-purified from pooled bone marrow cells (3-5 mice per group) and stimulated with the indicated amounts of the TLR-9 ligand CpG-2216. Culture supernatants were collected after 24 hours of stimulation, and IFN-α (B), TNF-α (C), and IL-12p40 (D) concentrations were measured by ELISA. Data are representative of 2 independent experiments. (E-G) Bone marrow pDCs were purified from intact female CD11c-ERαKO or ERαfl/fl control mice, and the production of IFN-α (E) and TNF-α (F) on TLR-9 stimulation was analyzed by ELISA. (G) Intact CD11c-ERαKO (n = 5) or ERαfl/fl (n = 4) female mice were injected intravenously with 2 μg of CpG-2216, and their serum IFNα concentration was then assessed by ELISA at the indicated time points.

stimulation of their endosomal TLR-9 not only ex vivo but also in situ.

Discussion

In this paper, we have analyzed the role of estrogens in the regulation of the TLR-mediated responses of human and mouse pDCs in vivo. Our data demonstrate that endogenous and exogenous estrogens were able to markedly enhance the endosomal

TLR-7– and TLR-9–mediated responses of pDCs during their steady state development. By using gene-targeted mice, we provided direct in vivo evidence for estradiol-dependent modulation of the TLR-mediated responses of pDCs through a mechanism involving pDC-intrinsic expression of ERα.

Previous works by others failed to report significant sex-dependent difference in the TLR-9–mediated response of human pDCs.[22,23] In our clinical study in postmenopausal women, titrated amounts of CpG were used to stimulate PBMCs, which are much lower than the doses used in previous studies.[22,23] In

some patients, the enhancing effect of E_2 treatment on IFN-α production was even more evident for the lowest concentration of CpG, which induced barely detectable levels of IFN-α in most PBMCs from untreated donors. Because this effect of E_2 treatment was not attributable to an increase of circulating human pDC numbers in PBMCs, our data suggest that E_2 treatment had decreased the threshold of TLR-9 responsiveness in human pDCs. Our experiments in mice are consistent with this hypothesis and demonstrate enhanced TLR-9–mediated responses of pDCs from E_2-treated mice through a mechanism that required pDC-intrinsic expression of ERα. Thus, the impact of female sex hormones on the TLR-9–mediated response of human pDCs could have been masked in previous studies because of differences in experimental settings.[22,23]

In line with previous works,[22] we did not detect any substantial effect of E_2 on the TLR-mediated responses of pDCs on short-term in vitro exposure. This observation suggests that the effect of E_2 is somehow imprinted in vivo and independent of the presence of E_2 at the time of TLR triggering in vitro. E_2 mediates its effect through 2 main nuclear receptors, ERα and ERβ. We present compelling evidence that ERα expression in the hematopoietic compartment is required for the enhancing effect of estrogens on the TLR-mediated responses of pDCs, suggesting a direct action of the hormone on pDCs or their precursors in the bone marrow. pDCs can be produced from the same myeloid progenitors in the bone marrow that give rise to monocytes and DC precursors.[36] It has been recently shown that myeloid progenitors defined as Lin$^-$ c-kit^{hi} Flt3$^+$ cells expressed high levels of $ER\alpha$, but not $ER\beta$, transcripts[34] and responded to E_2 by inducing the expression of the transcription factor IRF-4, which is critical for DC development in the presence of GM-CSF.[37,38] Indeed, we and others have shown that E_2 is required for normal development of murine inflammatory DCs in vitro in the presence of GM-CSF, through ERα, but not ERβ.[37,39] In the presence of Flt3L, monocytes and DC precursors give rise to the common DC precursors from which pDCs and pre-cDCs develop in the bone marrow.[36,40] We did not notice any deficiency in the homeostatic numbers of pDCs in the bone marrow and spleen in the absence of hematopoietic ERα, suggesting that ERα signaling was dispensable for normal homeostatic pDC development. In striking contrast, we observed that ERα activation in cells already committed to the pDC lineage critically regulated the TLR-mediated response of pDCs, not only in the bone marrow, but also in the periphery. In the CD11c-ERα^{KO} murine model, $ER\alpha$ inactivation probably occurs at a later stage of pDC development, probably after the common DC precursor stage because common DC precursors have been shown to lack CD11c expression.[40] Therefore, we postulate that the E_2-mediated increase in TLR-mediated responsiveness of pDCs is dependent on ERα activation occurring at a development stage between the putative committed pDC progenitor and terminally differentiated pDC state in the bone marrow[41] and still persists in peripheral pDCs.

In vivo enhancing effects of E_2 on innate immune functions of myeloid cells have been previously reported in mice.[42,43] We and others have shown in vivo E_2 administration to increase TLR-4–induced pro-inflammatory cytokine production by murine macrophages and microglia through ERα.[42,43] Using conditional $ER\alpha$-mutant mice, we recently demonstrated this in vivo effect of E_2 to be mediated through ERα signaling in macrophages.[44] However, in the present study, we did not detect any significant difference in the TLR-7/TLR-8–mediated response of blood monocytes between premenopausal and postmenopausal women, whether they were treated or not with E_2. This is in agreement with the previous study by Meier et al, which failed to uncover any changes in the endosomal TLR-7/TLR-8–mediated response of human monocytes or myeloid DCs between women and men.[23] These observations suggest that estrogens, at least in human, may selectively condition pDCs in vivo, but not other myeloid cells, such as monocytes, to enhance their capacity to respond to nucleic acids after stimulation of their endosomal TLRs.

Of note, we demonstrate that E_2 treatment in vivo increases the production of type I IFNs by human pDCs after TLR-7 or TLR-9 activation, not only by synthetic ligands, but also by nucleic acid-containing immune complexes. This potent regulatory effect of estrogens may account for a large part of the substantial sex-dependent dimorphism in SLE. Indeed, estrogens represent a known risk factor for lupus in both women and mice.[15,17,18,45] Our results identify a mechanism by which estrogens could exert such a profound modulatory effect through their action on the innate function of pDCs. A large body of evidence supports a central role for pDC-derived type I IFNs in SLE, and inhibition of TLR signaling in pDCs using TLR antagonists has been shown to represent a promising strategy for SLE treatment.[4,46] Our data suggest that antagonizing ER signaling in vivo could represent an alternative approach for the down-regulation of TLR-dependent pDC activation in SLE.

Lastly, because of the pivotal role of pDCs in viral infections, up-regulation of the TLR-7 pathway in pDCs might improve anti–viral immunity in patients chronically infected with hepatitis C virus. Indeed, it has been recently shown that pDCs can sense hepatitis C virus-infected cells in the liver and produce IFN-α/β, thereby inhibiting infection of neighboring hepatocytes.[47] We think that the potent regulatory effect of estrogens on TLR-mediated IFN-α production by human pDCs may account for the substantial sex bias observed in the pathogenesis of hepatitis C virus.[48] This could also explain the intriguing observation that hormone replacement therapy is beneficial in postmenopausal women with chronic hepatitis C.[49,50]

In conclusion, our data highlight a previously unappreciated role for estrogens in promoting the innate functions of pDCs. This observation should open avenues to the development of therapeutic approaches aimed at modulating TLR signaling in pDCs, using selective ER modulators, for the optimal management of various diseases where this important DC subset plays a pivotal role.

Acknowledgments

Authorship

References

1. Gilliet M, Cao W, Liu YJ. Plasmacytoid dendritic cells: sensing nucleic acids in viral infection and autoimmune diseases. *Nat Rev Immunol.* 2008; 8(8):594-606.

2. Marshak-Rothstein A. Toll-like receptors in systemic autoimmune disease. *Nat Rev Immunol.* 2006;6(11):823-835.

3. Blanco P, Palucka AK, Gill M, Pascual V, Bancherau J. Induction of dendritic cell differentiation by IFN-alpha in systemic lupus erythematosus. *Science.* 2001;294(5546):1540-1543.

4. Barrat FJ, Coffman RL. Development of TLR inhibitors for the treatment of autoimmune diseases. *Immunol Rev.* 2008;223:271-283.

5. Hooks JJ, Moutsopoulos HM, Geis SA, Stahl NI, Decker JL, Notkins AL. Immune interferon in the circulation of patients with autoimmune disease. *N Engl J Med.* 1979;301(1):5-8.

6. Ytterberg SR, Schnitzer TJ. Serum interferon levels in patients with systemic lupus erythematosus. *Arthritis Rheum.* 1982;25(4):401-406.

7. Baechler EC, Batliwalla FM, Karypis G, et al. Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus. *Proc Natl Acad Sci U S A.* 2003;100(5): 2610-2615.

8. Bennett L, Palucka AK, Arce E, et al. Interferon and granulopoiesis signatures in systemic lupus erythematosus blood. *J Exp Med.* 2003;197(6): 711-723.

9. Ioannou Y, Isenberg DA. Current evidence for the induction of autoimmune rheumatic manifestations by cytokine therapy. *Arthritis Rheum.* 2000; 43(7):1431-1442.

10. Mathian A, Weinberg A, Gallegos M, Bancherau J, Koutouzov S. IFN-alpha induces early lethal lupus in preautoimmune (New Zealand Black x New Zealand White) F1 but not in BALB/c mice. *J Immunol.* 2005;174(5):2499-2506.

11. Fairhurst AM, Mathian A, Connolly JE, et al. Systemic IFN-alpha drives kidney nephritis in B6.Sle123 mice. *Eur J Immunol.* 2008;38(7): 1948-1960.

12. Lopez P, Gomez J, Prado C, Gutierrez C, Suarez A. Influence of functional interleukin 10/tumor necrosis factor-alpha polymorphisms on interferon-alpha, IL-10, and regulatory T cell population in patients with systemic lupus erythematosus receiving antimalarial treatment. *J Rheumatol.* 2008;35(8):1559-1566.

13. Studnicka-Benke A, Steiner G, Petera P, Smolen JS. Tumour necrosis factor alpha and its soluble receptors parallel clinical disease and autoimmune activity in systemic lupus erythematosus. *Br J Rheumatol.* 1996;35(11): 1067-1074.

14. Aringer M, Smolen JS. The role of tumor necrosis factor-alpha in systemic lupus erythematosus. *Arthritis Res Ther.* 2008;10(1):202.

15. Whitacre CC. Sex differences in autoimmune disease. *Nat Immunol.* 2001;2(9):777-780.

16. Fish EN. The X-files in immunity: sex-based differences predispose immune responses. *Nat Rev Immunol.* 2008;8(9):737-744.

17. Costenbader KH, Feskanich D, Stampfer MJ, Karlson EW. Reproductive and menopausal factors and risk of systemic lupus erythematosus in women. *Arthritis Rheum.* 2007;56(4):1251-1262.

18. Roubinian JR, Talal N, Greenspan JS, Goodman JR, Siiteri PK. Effect of castration and sex hormone treatment on survival, anti–nucleic acid antibodies, and glomerulonephritis in NZB/NZW F1 mice. *J Exp Med.* 1978;147(6):1568-1583.

19. Carlsten H, Nilsson N, Jonsson R, Backman K, Holmdahl R, Tarkowski A. Estrogen accelerates immune complex glomerulonephritis but ameliorates T cell-mediated vasculitis and sialadenitis in autoimmune MRL lpr/lpr mice. *Cell Immunol.* 1992;144(1):190-202.

20. Farzadegan H, Hoover DR, Astemborski J, et al. Sex differences in HIV-1 viral load and progression to AIDS. *Lancet.* 1998;352(9139):1510-1514.

21. Gandhi M, Bacchetti P, Miotti P, Quinn TC, Veronese F, Greenblatt RM. Does patient sex affect human immunodeficiency virus levels? *Clin Infect Dis.* 2002;35(3):313-322.

22. Berghofer B, Frommer T, Haley G, Fink L, Bein G, Hackstein H. TLR-7 ligands induce higher IFN-alpha production in females. *J Immunol.* 2006; 177(4):2088-2096.

23. Meier A, Chang JJ, Chan ES, et al. Sex differences in the Toll-like receptor-mediated response of plasmacytoid dendritic cells to HIV-1. *Nat Med.* 2009;15(8):955-959.

24. Palucka AK, Gatlin J, Blanck JP, et al. Human dendritic cell subsets in NOD/SCID mice engrafted with CD34+ hematopoietic progenitors. *Blood.* 2003;102(9):3302-3310.

25. Dupont S, Krust A, Gansmuller A, Dierich A, Chambon P, Mark M. Effect of single and compound knockouts of estrogen receptors alpha (ERalpha) and beta (ERbeta) on mouse reproductive phenotypes. *Development.* 2000;127(19): 4277-4291.

26. Lelu K, Laffont S, Delpy L, et al. Estrogen receptor alpha signaling in T lymphocytes is required for estradiol-mediated inhibition of Th1 and Th17 cell differentiation and protection against experimental autoimmune encephalomyelitis. *J Immunol.* 2011;187(5):2386-2393.

27. Elhage R, Arnal JF, Pieraggi MT, et al. 17 beta-estradiol prevents fatty streak formation in apolipoprotein E-deficient mice. *Arterioscler Thromb Vasc Biol.* 1997;17(11):2679-2684.

28. Lovgren T, Eloranta ML, Bave U, Alm GV, Ronnblom L. Induction of interferon-alpha production in plasmacytoid dendritic cells by immune complexes containing nucleic acid released by necrotic or late apoptotic cells and lupus IgG. *Arthritis Rheum.* 2004;50(6):1861-1872.

29. Asselin-Paturel C, Brizard G, Chemin K, et al. Type I interferon dependence of plasmacytoid dendritic cell activation and migration. *J Exp Med.* 2005;201(7):1157-1167.

30. Cros J, Cagnard N, Woollard K, et al. Human CD14dim monocytes patrol and sense nucleic acids and viruses via TLR-7 and TLR-8 receptors. *Immunity.* 2010;33(3):375-386.

31. Decalf J, Fernandes S, Longman R, et al. Plasmacytoid dendritic cells initiate a complex chemokine and cytokine network and are a viable drug target in chronic HCV patients. *J Exp Med.* 2007; 204(10):2423-2437.

32. Vallin H, Blomberg S, Alm GV, Cederblad B, Ronnblom L. Patients with systemic lupus erythematosus (SLE) have a circulating inducer of interferon-α (IFN-α) production acting on leucocytes resembling immature dendritic cells. *Clin Exp Immunol.* 1999;115(1):196-202.

33. Vallin H, Perers A, Alm GV, Ronnblom L. Anti–double-stranded DNA antibodies and immunostimulatory plasmid DNA in combination mimic the endogenous IFN-alpha inducer in systemic lupus erythematosus. *J Immunol.* 1999;163(11):6306-6313.

34. Carreras E, Turner S, Paharkova-Vatchkova V, Mao A, Dascher C, Kovats S. Estradiol acts directly on bone marrow myeloid progenitors to differentially regulate GM-CSF or Flt3 ligand-mediated dendritic cell differentiation. *J Immunol.* 2008;180(2):727-738.

35. Caton ML, Smith-Raska MR, Reizis B. Notch-RBP-J signaling controls the homeostasis of CD8− dendritic cells in the spleen. *J Exp Med.* 2007;204(7):1653-1664.

36. Fogg K, Sibon C, Miled C, et al. A clonogenic bone marrow progenitor specific for macrophages and dendritic cells. *Science.* 2006; 311(5757):83-87.

37. Paharkova-Vatchkova V, Maldonado R, Kovats S. Estrogen preferentially promotes the differentiation of CD11c(+) CD11b(intermediate) dendritic cells from bone marrow precursors. *J Immunol.* 2004;172(3):1426-1436.

38. Carreras E, Turner S, Frank MB, et al. Estrogen receptor signaling promotes dendritic cell differentiation by increasing expression of the transcription factor IRF4. *Blood.* 2009;115(2):238-246.

39. Douin-Echinard V, Laffont S, Seillet C, et al. Estrogen receptorα, but not β, is required for optimal dendritic cell differentiation and CD40-induced cytokine production. *J Immunol.* 2008;180(6): 3661-3669.

40. Liu K, Victora GD, Schwickert TA, et al. In vivo analysis of dendritic cell development and homeostasis. *Science.* 2009;324(5925):392-397.

41. Reizis B, Bunin A, Ghosh HS, Lewis KL, Sisirak V. Plasmacytoid dendritic cells: recent progress and open questions. *Annu Rev Immunol.* 2011;29:163-183.

42. Calippe B, Douin-Echinard V, Laffargue M, et al. Chronic estradiol administration in vivo promotes the proinflammatory response of macrophages to TLR4 activation: involvement of the phosphatidylinositol 3-kinase pathway. *J Immunol.* 2008; 180(12):7980-7988.

43. Soucy G, Boivin G, Labrie F, Rivest S. Estradiol is required for a proper immune response to bacterial and viral pathogens in the female brain. *J Immunol.* 2005;174(10):6391-6398.

44. Calippe B, Douin-Echinard V, Delpy L, et al. 17Beta-estradiol promotes TLR4-triggered proinflammatory mediator production through direct

estrogen receptor alpha signaling in macrophages in vivo. *J Immunol.* 2010;185(2):1169-1176.

45. Bynote KK, Hackenberg JM, Korach KS, Lubahn DB, Lane PH, Gould KA. Estrogen receptor-alpha deficiency attenuates autoimmune disease in (NZB x NZW)F1 mice. *Genes Immun.* 2008;9(2):137-152.

46. Guiducci C, Gong M, Xu Z, et al. TLR recognition of self nucleic acids hampers glucocorticoid activity in lupus. *Nature.* 2010;465(7300):937-941.

47. Takahashi K, Asabe S, Wieland S, et al. Plasmacytoid dendritic cells sense hepatitis C virus-infected cells, produce interferon, and inhibit infection. *Proc Natl Acad Sci U S A.* 2010;107(16): 7431-7436.

48. Davis GL, Alter MJ, El-Serag H, Poynard T, Jennings LW. Aging of hepatitis C virus (HCV)-infected persons in the United States: a multiple cohort model of HCV prevalence and disease progression. *Gastroenterology.* 2010;138(2):513-521.

49. Di Martino V, Lebray P, Myers RP, et al. Progression of liver fibrosis in women infected with hepatitis C: long-term benefit of estrogen exposure. *Hepatology.* 2004;40(6):1426-1433.

50. Codes L, Asselah T, Cazals-Hatem D, et al. Liver fibrosis in women with chronic hepatitis C: evidence for the negative role of the menopause and steatosis and the potential benefit of hormone replacement therapy. *Gut.* 2007;56(3): 390-395.

The TLR-mediated response of plasmacytoid dendritic cells is positively regulated by estradiol in vivo through cell-intrinsic estrogen receptor α signaling

Cyril Seillet, Sophie Laffont, Florence Trémollières, Nelly Rouquié, Claude Ribot, Jean-François Arnal, Victorine Douin-Echinard, Pierre Gourdy and Jean-Charles Guéry

Updated information and services can be found at:
http://www.bloodjournal.org/content/119/2/454.full.html

Articles on similar topics can be found in the following Blood collections
Immunobiology and Immunotherapy (5647 articles)

Information about reproducing this article in parts or in its entirety may be found online at:
http://www.bloodjournal.org/site/misc/rights.xhtml#repub_requests

Information about ordering reprints may be found online at:
http://www.bloodjournal.org/site/misc/rights.xhtml#reprints

Information about subscriptions and ASH membership may be found online at:
http://www.bloodjournal.org/site/subscriptions/index.xhtml